Relay Therapeutics 

Relay Therapeutics 

Yahoo Finance • last month

Relay Therapeutics Prices $275 Mln Offering Of Shares At $12 Per Share

(RTTNews) - Relay Therapeutics, Inc. (RLAY), a clinical-stage, small-molecule precision medicine company, priced its public offering of 22.92 million shares of common stock at a public offering price of $12 per share. The gross proceeds fr... Full story

Yahoo Finance • last month

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and ge... Full story

Yahoo Finance • last month

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.1% and the State S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Rising Bond Yields Weigh on Stocks

The S&P 500 Index ($SPX) (SPY) today is down -0.68%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.34%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.95%.  June E-mini S&P futures (ESM26) are down -0.75%, and June E-mini Na... Full story

Yahoo Finance • last month

Stocks Pressured by Tech Weakness and Rising Bond Yields

The S&P 500 Index ($SPX) (SPY) today is down -0.35%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.45%.  June E-mini S&P futures (ESM26) are down -0.40%, and June E-mini Na... Full story

Yahoo Finance • last month

Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million

SB Investment Advisers (UK) Ltd reported a sale of 2,168,884 shares of Vir Biotechnology(NASDAQ:VIR) in its May 15, 2026, SEC filing, an estimated $17.28 million trade based on quarterly average pricing. What happened According to an SEC... Full story

Yahoo Finance • 2 months ago

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Quick Read All three biotechs have dense 2026 clinical and regulatory milestone calendars that can drive outsized share movements, with cash runways stretching into 2028-2029 and strong analyst support despite pre-revenue status and binar... Full story

Yahoo Finance • 2 months ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • 4 months ago

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story

Yahoo Finance • 4 months ago

Erasca, Inc. (ERAS): A Bull Case Theory

We came across a bullish thesis on Erasca, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on ERAS. Erasca, Inc.'s share was trading at $12.39 as of February 19th.Cidara (CDTX) Climbs 105% on $... Full story

Yahoo Finance • 4 months ago

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story

Yahoo Finance • 7 months ago

Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways... Full story

Yahoo Finance • 8 months ago

Relay Therapeutics GAAP EPS of -$0.43 misses by $0.02

* Relay Therapeutics press release [https://seekingalpha.com/pr/20297824-relay-therapeutics-reports-third-quarter-2025-financial-results-and-corporate-updates] (RLAY [https://seekingalpha.com/symbol/RLAY]): Q3 GAAP EPS of -$0.43 misses by... Full story

Yahoo Finance • 8 months ago

Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025

CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • 10 months ago

Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week

Key Points An analyst initiated coverage of the biotech. Not only does he consider it a buy, he's also designated it as one of his firm's top picks.10 stocks we like better than Relay Therapeutics › Precision medicine specialist Relay Th... Full story

Yahoo Finance • 10 months ago

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and g... Full story

Yahoo Finance • 11 months ago

Relay Therapeutics’ SWOT analysis: AI-driven biotech’s stock faces pivotal phase

Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotechnology company specializing in precision medicine and AI-driven drug discovery, stands at a critical juncture in its development. With its lead candidate RLY-2608 progressing through clinica... Full story

Yahoo Finance • 11 months ago

Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates

Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase3ReDiscover-2trial in Q2 Approximately $657... Full story

Yahoo Finance • 11 months ago

Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025

CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental tec... Full story

Yahoo Finance • last year

Relay Therapeutics' SWOT analysis: AI-driven drug discovery stock faces pivotal phase

Relay Therapeutics, Inc. (NASDAQ:RLAY), a biotechnology company with a market capitalization of $552 million focused on AI-driven drug discovery, stands at a critical juncture in its development of RLY-2608, a mutant-selective PI3Ka inhibi... Full story